Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Below 50 Day Moving Average – Time to Sell?

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.90 and traded as low as $3.55. Voyager Therapeutics shares last traded at $3.62, with a volume of 569,541 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on VYGR shares. Wall Street Zen cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, May 26th. Finally, Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Price Performance

The company has a market capitalization of $201.20 million, a price-to-earnings ratio of -1.69 and a beta of 1.25. The firm’s fifty day moving average price is $3.88 and its 200-day moving average price is $3.96.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $8.79 million. Voyager Therapeutics had a negative return on equity of 55.97% and a negative net margin of 319.61%. On average, research analysts predict that Voyager Therapeutics, Inc. will post -1.62 earnings per share for the current year.

Insider Transactions at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 11,511 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the completion of the transaction, the chief executive officer owned 472,549 shares in the company, valued at $1,828,764.63. This trade represents a 2.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 179.3% in the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after acquiring an additional 317,927 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in shares of Voyager Therapeutics in the 1st quarter worth approximately $218,000. Acadian Asset Management LLC lifted its position in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after purchasing an additional 206,758 shares during the period. Geode Capital Management LLC boosted its stake in shares of Voyager Therapeutics by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after purchasing an additional 11,929 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Voyager Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after buying an additional 6,748 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.